Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: corticosteroids

Lupus Update: Findings from the Latest Phase 3 Clinical Trials

Michele B. Kaufman, PharmD, BCGP  |  October 11, 2024

Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:dapirolizumab pegolEnd-stage renal diseasekidneyLupus nephritisobinutuzumabsystemic lupus erythematosus (SLE)

Making Sense of Autoimmune Sensorineural Hearing Loss

Bryn Nelson, PhD  |  October 8, 2024

An unusual autoimmune inner ear condition results in hearing loss, but is reversible if treated.

Filed under:ConditionsOther Rheumatic ConditionsVasculitis Tagged with:autoimmune inner ear diseaseautoimmune sensorineural hearing loss (SNHL)hearing loss

The Rheumatologist’s Role in Sarcoidosis

Samantha C. Shapiro, MD  |  August 26, 2024

Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsOther Rheumatic Conditions Tagged with:EULAREULAR 2024

Helping Patients with SLE Thrive

Jason Liebowitz, MD, FACR  |  July 31, 2024

Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:EULAR 2024Lupus Low Disease-Activity State (LLDAS)SLESLE Resource Centersystemic lupus erythematosus (SLE)

FDA Approves Sarilumab for pJIA

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2024

The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)sarilumabU.S. Food and Drug Administration (FDA)

Case Report: Diaphragm Ultrasound Reveals Shrinking Lung Syndrome

Mery Deeb, MD, Taro Minami, MD, Michael Stanchina, MD, Elias Jabbour, MD, & Jan Karczewski, MD  |  July 9, 2024

Shrinking lung syndrome (SLS) is a rare cause of dyspnea that has been most commonly described in patients with systemic lupus erythematosus (SLE), but is also found in systemic sclerosis, Sjögren’s disease and rheumatoid arthritis. Shrinking lung syndrome is characterized by a restrictive pattern on lung spirometry, despite normal lung parenchyma, and an elevated diaphragm.1…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportdyspneashrinking lung syndromeSLE Resource CenterUltrasound

When Rheumatologists Have Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  June 10, 2024

  “I think we learn from medicine everywhere that it is, at its heart, a human endeavor, requiring good science but also a limitless curiosity and interest in your fellow human being, and that the physician-patient relationship is key; all else follows from it.”1 These profound words from Abraham Verghese, MD, MACP, Linda R. Meier…

Filed under:CareerPatient PerspectiveProfiles Tagged with:Empathypatient-clinician relationshipphysician patient relationship

Case Report: Complicated Presentation Eventually Explained by Rare Syndrome

Geoffrey E. Thiele, MD, & Iris Reyhan, MD  |  April 10, 2024

Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportCrohn's diseasePachydermoperiostosisprimary hypertrophic osteoarthropathyTouraine-Solente- Golé syndrome

Can Repeat Injections Improve Knee OA Pain?

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2024

Promising Results from a Phase 3 Study SAN DIEGO—An investigational liposomal formulation of dexamethasone sodium phosphate (TLC599) for intra-articular injection is being studied to treat patients with knee osteoarthritis (OA). George Spencer-Green, MD, MS, chief medical officer of Taiwan Liposome Company (TLC), Cambridge, Mass., presented recent data on this agent in a late-breaking abstract session…

Filed under:ACR ConvergenceAnalgesicsConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2023corticosteroid injectionKnee Osteoarthritis (OA)

How to Treat Refractory Polymyalgia Rheumatica

Katie Robinson  |  January 25, 2024

Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:glucocorticoid resistantIL-6IL-6 inhibitorsPMR FocusRheumPolymyalgia RheumaticaResearch Reviewsarilumab

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences